Glaukos Corporation vs Eli Lilly & Co.
GKOS vs LLY — side-by-side comparison from reported financials. GKOS leads 2, LLY leads 6 of 8 comparable metrics.
Glaukos Corporation
GKOS · Healthcare
$165.69+2.73%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | GKOS | LLY |
|---|---|---|
| Price | $165.69 | $1 177.20 |
| Market cap | $9.77B | $1.05T |
| Revenue (TTM) | $613M | $79.7B |
| Revenue growth | +21.5% | +31.7% |
| Net margin | -30.7% | 33.5% |
| Free cash flow | -$12.2M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +90.4% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | — | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -27% | 93% |
| Altman Z-score | 23.88 | 7.10 |
| CV checks passed | 4 of 9 | 11 of 9 |
| Employees | 1,094 | 50,000 |
Full résumé-style profiles: GKOS CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.